Skip to main content

Patricia Pozo Rosich

I am a doctor of medicine, specialist in neurology. I am head of the Neurology Service of Vall d'Hebron. I lead the Research Laboratory in Cephalea and Neurological Pain of the VHIR (Vall d’Hebron Research Institute) belonging to the Autonomous University of Barcelona (UAB).

Institutions of which they are part

Head of group
Headache and Neurological Pain
Vall Hebron Institut de Recerca
Neurology
General Hospital
Patricia Pozo Rosich

Patricia Pozo Rosich

Patricia Pozo Rosich

Institutions of which they are part

Head of group
Headache and Neurological Pain
Vall Hebron Institut de Recerca
Neurology
General Hospital

I am a doctor of medicine, specialist in neurology. I am head of the Neurology Service of Vall d'Hebron. I lead the Research Laboratory in Cephalea and Neurological Pain of the VHIR (Vall d’Hebron Research Institute) belonging to the Autonomous University of Barcelona (UAB).

I am a member of the Executive Committee of the International Headache Society and the European Headache Federation and of the Committee for Clinical Trials of the International Headache Society. In addition, I am a member of the American Headache Society.

I specialized in the field of headache in the United States and London, in the laboratories of Professor Silberstein (Thomas Jefferson University) and Professor Goadsby (University of California at San Francisco and University College London – Queen Square), with the help of the “la Caixa” scholarships, AHS, EFNS, Rio Hortega, GECSEN.

My interest in the field of research focuses on better understanding the pathophysiology of migraine from a multidisciplinary approach using genetics, neuroimaging and electrophysiology. I have developed the Migraine Adaptive Brain research program that focuses on the neurosensory brain. I am a member of the International Consortium of Migration Genetics.

To carry out research projects I have received grants from the “la Caixa” Banking Foundation, the FIS (Health Research Fund) of the Carlos III Institute, the La MaratóTV3 Foundation, Migraine Research Foundation, MICINN (Ministry of Science and Innovation) and the Mutual Medical.

I am editor of the journals Frontiers in Neurology, Journal of Headache and Pain and director of the Cephalia Area of the Neurology Journal. I have published original articles in impact factor journals, review articles, book chapters, edited books and magazines and I am the author of books.

I also work in education. I am a clinical associate professor at the Autonomous University of Barcelona.

Projects

FUNAMIG: análisis funcional del estudio CHROMIG (genotipado del riesgo de desarrollar migraña crónica)

IP: Patricia Pozo Rosich
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 98615
Reference: PI10/00876
Duration: 01/01/2011 - 30/06/2015

Genes y migraña: clonaje posicional en migraña familiar y expresión en la depresión cortical propagada experimental

IP: Alfons Macaya Ruíz
Collaborators: Patricia Pozo Rosich, Susana Boronat Guerero, Miquel Raspall Chaure, Marta Vila Pueyo
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 90750.02
Reference: SAF2009-13182-C03-03
Duration: 01/01/2010 - 31/12/2012

Ministerio de Ciencia

CHROMIG: genotipatge del risc de desenvolupar migranya crònica

IP: Patricia Pozo Rosich
Collaborators: Manuel Quintana Luque
Funding agency: Fundació La Marató de TV3
Funding: 199413.75
Reference: MARATV3_072310
Duration: 16/01/2008 - 31/03/2012

Neuroimatge amb SPECT en cefalea per abús de medicaments

IP: Joan Castell Conesa
Collaborators: Patricia Pozo Rosich, Carles Lorenzo Bosquet
Funding agency: Fundació La Marató de TV3
Funding: 199800
Reference: MARATV3_072210
Duration: 16/01/2008 - 31/12/2011

Related news

Two international studies led by Vall d'Hebron recommend early administration of specific drugs to prevent migraine to achieve a better response to therapy.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

The study, conducted in more than 770 people, concludes that atogepant reduces the frequency of migraine attacks and the need to take medication.

Related professionals

Mª Carmen López  Arribas

Mª Carmen López Arribas

Research technician
Molecular Medical Imaging
Read more
Teresa Vendrell Bayona

Teresa Vendrell Bayona

Genetics Medicine
Read more
Josep Castellví Vives

Josep Castellví Vives

Translational Molecular Pathology
Read more
M Jesus Arevalo  Navines

M Jesus Arevalo Navines

Postdoctoral researcher
Clinical Neuroimmunology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.